Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
You may also be interested in...
Another Disappointment For Pfizer; PAH Drug Withdrawn
Pfizer withdraws Thelin from the EU, Canada and Australia due to liver toxicity.
Another Disappointment For Pfizer; PAH Drug Withdrawn
Pfizer withdraws Thelin from the EU, Canada and Australia due to liver toxicity.
Encysive Rules Out FDA Dispute Resolution Path For Thelin NDA
Firm expects to have 35 sales reps for European, Canadian launch of Thelin by early next year, CEO says.